Thromboembolic prophylaxis with dihydroergotamine-heparin in abdominal surgery. A controlled, randomized study

Area of Science:

• Thrombosis and Hemostasis
• Surgical Prophylaxis

Background:

• Postoperative thromboembolic complications remain a significant risk following gastrointestinal surgery.
• Heparin is a standard prophylactic agent, but optimal dosing and combinations are continuously investigated.

Purpose of the Study:

• To compare the efficacy and safety of a dihydroergotamine-heparin combination versus standard heparin for preventing deep venous thrombosis (DVT) after gastrointestinal surgery.

Main Methods:

• A controlled, randomized study involving 100 patients undergoing gastrointestinal surgery.
• Group 1 (50 patients): received dihydroergotamine-heparin (0.5 mg + 5,000 units) twice daily.
• Group 2 (50 patients): received 5,000 units of heparin three times daily.
• Deep venous thrombosis was assessed using the radiofibrinogen uptake test.

Main Results:

• The dihydroergotamine-heparin group showed a DVT rate of 12% compared to 18% in the heparin-only group (p > 0.05).
• Wound hematoma occurred in 2% of the dihydroergotamine-heparin group and 4% of the heparin group.
• No other significant hemorrhagic complications were observed in either group.

Conclusions:

• Combining heparin with dihydroergotamine provides effective prophylaxis against thromboembolism.
• This combination allows for a one-third reduction in the daily heparin dose while maintaining therapeutic benefits.
• The dihydroergotamine-heparin regimen demonstrated a favorable safety profile with a low incidence of bleeding complications.